Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade in Previously Untreated Multiple Myeloma
NCT00153920Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2003
- Primary completion
- Jul 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate. Started Dec 2003; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00153920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00153920.